<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Fennec Pharmaceuticals Inc.

    Fennec Pharmaceuticals Inc.

    Fennec Pharmaceuticals, Inc., (NASDAQ: FENC; TSX: FRX) is a specialty pharmaceutic...

    Fennec Pharmaceuticals, Inc., (NASDAQ: FENC; TS...

    Filing Type:    PU
    Vanda Pharmaceuticals Inc.

    Vanda Pharmaceuticals Inc.

    Vanda is developing important new medicines to improve the lives of patients. We u...

    Vanda is developing important new medicines to ...

    Filing Type:    PU
    Evofem Biosciences, Inc.

    Evofem Biosciences, Inc.

    Evofem BiosciencesÂŽ exists to advance the lives of women. We believe this work ce...

    Evofem BiosciencesÂŽ exists to advance the live...

    Filing Type:    PU
    LeMaitre Vascular, Inc.

    LeMaitre Vascular, Inc.

    LeMaitre Vascular is a leading global innovator, manufacturer and marketer of devi...

    LeMaitre Vascular is a leading global innovator...

    Filing Type:    PU
    Editas Medicine, Inc.

    Editas Medicine, Inc.

    As a leading genome editing company, Editas Medicine is focused on translating the...

    As a leading genome editing company, Editas Med...

    Filing Type:    PU
    Soliton, Inc.

    Soliton, Inc.

    Soliton, Inc. is a medical device company with a novel and proprietary platform te...

    Soliton, Inc. is a medical device company with ...

    Filing Type:    PU
    Merck KGaA

    Merck KGaA

    Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates...

    Merck KGaA, Darmstadt, Germany, a leading scien...

    Filing Type:    PU
    NextCure, Inc.

    NextCure, Inc.

    NextCure is a clinical-stage biopharmaceutical company committed to discovering an...

    NextCure is a clinical-stage biopharmaceutical ...

    Filing Type:    PU
    Inovio Pharmaceuticals, Inc.

    Inovio Pharmaceuticals, Inc.

    Inovio is bringing IMMUNO-INGENUITY™ to life and is reshaping the future of trea...

    Inovio is bringing IMMUNO-INGENUITY™ to life ...

    Filing Type:    PU
    Benitec Biopharma Limited

    Benitec Biopharma Limited

    Benitec is a biotechnology company developing a proprietary therapeutic technology...

    Benitec is a biotechnology company developing a...

    Filing Type:    PU
    Immunomedics, Inc.

    Immunomedics, Inc.

    Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal a...

    Immunomedics is a clinical-stage biopharmaceuti...

    Filing Type:    PU
    Exelixis, Inc.

    Exelixis, Inc.

    Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncol...

    Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) ...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.